The therapeutic effect of TNFR1-selective antagonistic mutant TNF-α in murine hepatitis models

Cytokine

Volumn 44, Issue 2, 2008, Pages 229-233

  Shibata, Hiroko ^a,b   Yoshioka, Yasuo ^a,c   Ohkawa, Akiko ^a,c   Abe, Yasuhiro ^a,c   Nomura, Tetsuya ^a,c   Mukai, Yohei ^a,c   Nakagawa, Shinsaku ^c   Taniai, Madoka ^d   Ohta, Tsunetaka ^d   Mayumi, Tadanori ^e   Kamada, Haruhiko ^a,c   Tsunoda, Shin ichi ^a,c   Tsutsumi, Yasuo ^a,c  

^a NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

^b NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

^c OSAKA UNIVERSITY   (Japan)

^d HAYASHIBARA BIOCHEMICAL LABORATORIES INC   (Japan)

^e KOBE GAKUIN UNIVERSITY   (Japan)

Author keywords

Inflammation; Liver failure; Therapy; Tumor necrosis factor

Indexed keywords

ALANINE AMINOTRANSFERASE; BIOLOGICAL MARKER; CARBON TETRACHLORIDE; CONCANAVALIN A; INTERLEUKIN 2; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ACUTE HEPATITIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THERAPY EFFECT;

ALANINE TRANSAMINASE; ANIMALS; CARBON TETRACHLORIDE; CELL LINE; CONCANAVALIN A; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; HEPATITIS, ANIMAL; HUMANS; MICE; MICE, INBRED BALB C; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; TUMOR NECROSIS FACTOR-ALPHA;

MURINAE;

EID: 55749087333     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2008.07.003     Document Type: Article

References (38)

1. Galun E., and Axelrod J.H. The role of cytokines in liver failure and regeneration: potential new molecular therapies. Biochim Biophys Acta 1592 (2002) 345-358
2. Vaquero J., and Blei A.T. Etiology and management of fulminant hepatic failure. Curr Gastroenterol Rep 5 (2003) 39-47
3. Lee W.M. Acute liver failure in the United States. Semin Liver Dis 23 (2003) 217-226
4. Tracey K.J., and Cerami A. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Annu Rev Med 45 (1994) 491-503
5. Aggarwal B.B. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 3 (2003) 745-756
6. Muto Y., Nouri-Aria K.T., Meager A., Alexander G.J., Eddleston A.L., and Williams R. Enhanced tumour necrosis factor and interleukin-1 in fulminant hepatic failure. Lancet 2 (1988) 72-74
7. Bird G.L., Sheron N., Goka A.K., Alexander G.J., and Williams R.S. Increased plasma tumor necrosis factor in severe alcoholic hepatitis. Ann Intern Med 112 (1990) 917-920
8. Gonzalez-Amaro R., Garcia-Monzon C., Garcia-Buey L., Moreno-Otero R., Alonso J.L., Yague E., et al. Induction of tumor necrosis factor alpha production by human hepatocytes in chronic viral hepatitis. J Exp Med 179 (1994) 841-848
9. Bradham C.A., Plumpe J., Manns M.P., Brenner D.A., and Trautwein C. Mechanisms of hepatic toxicity. I. TNF-induced liver injury. Am J Physiol 275 (1998) G387-G392
10. McClain C.J., Song Z., Barve S.S., Hill D.B., and Deaciuc I. Recent advances in alcoholic liver disease. IV. Dysregulated cytokine metabolism in alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol 287 (2004) G497-G502
11. Menon K.V., Stadheim L., Kamath P.S., Wiesner R.H., Gores G.J., Peine C.J., et al. A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis. Am J Gastroenterol 99 (2004) 255-260
12. Carroll MB, Bond MI. Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection. Semin Arthritis Rheum 2008, in press.
13. Keane J., Gershon S., Wise R.P., Mirabile-Levens E., Kasznica J., Schwieterman W.D., et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345 (2001) 1098-1104
14. Shakoor N., Michalska M., Harris C.A., and Block J.A. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 359 (2002) 579-580
15. Aggarwal B.B., Eessalu T.E., and Hass P.E. Characterization of receptors for human tumour necrosis factor and their regulation by gamma-interferon. Nature 318 (1985) 665-667
16. Wajant H., Pfizenmaier K., and Scheurich P. Tumor necrosis factor signaling. Cell Death Differ 10 (2003) 45-65
17. MacEwan D.J. TNF receptor subtype signalling: differences and cellular consequences. Cell Signal 14 (2002) 477-492
18. Bradley J. TNF-mediated inflammatory disease. J Pathol 214 (2008) 149-160
19. Yamamoto Y., Tsutsumi Y., Yoshioka Y., Nishibata T., Kobayashi K., Okamoto T., et al. Site-specific PEGylation of a lysine-deficient TNF-alpha with full bioactivity. Nat Biotechnol 21 (2003) 546-552
20. Shibata H., Yoshioka Y., Ikemizu S., Kobayashi K., Yamamoto Y., Mukai Y., et al. Functionalization of tumor necrosis factor-alpha using phage display technique and PEGylation improves its antitumor therapeutic window. Clin Cancer Res 10 (2004) 8293-8300
21. Shibata H., Yoshioka Y., Ohkawa A., Minowa K., Mukai Y., Abe Y., et al. Creation and X-ray structure analysis of the tumor necrosis factor receptor-1-selective mutant of a tumor necrosis factor-alpha antagonist. J Biol Chem 283 (2008) 998-1007
22. Vandenabeele P., Declercq W., Vanhaesebroeck B., Grooten J., and Fiers W. Both TNF receptors are required for TNF-mediated induction of apoptosis in PC60 cells. J Immunol 154 (1995) 2904-2913
23. Recknagel R.O., Glende Jr. E.A., Dolak J.A., and Waller R.L. Mechanisms of carbon tetrachloride toxicity. Pharmacol Ther 43 (1989) 139-154
24. Tiegs G., Hentschel J., and Wendel A. A T cell-dependent experimental liver injury in mice inducible by concanavalin A. J Clin Invest 90 (1992) 196-203
25. Mizuhara H., O'Neill E., Seki N., Ogawa T., Kusunoki C., Otsuka K., et al. T cell activation-associated hepatic injury: mediation by tumor necrosis factors and protection by interleukin 6. J Exp Med 179 (1994) 1529-1537
26. Wolf A.M., Wolf D., Rumpold H., Ludwiczek S., Enrich B., Gastl G., et al. The kinase inhibitor imatinib mesylate inhibits TNF-{alpha} production in vitro and prevents TNF-dependent acute hepatic inflammation. Proc Natl Acad Sci USA 102 (2005) 13622-13627
27. Bruccoleri A., Gallucci R., Germolec D.R., Blackshear P., Simeonova P., Thurman R.G., et al. Induction of early-immediate genes by tumor necrosis factor alpha contribute to liver repair following chemical-induced hepatotoxicity. Hepatology 25 (1997) 133-141
28. Yamada Y., and Fausto N. Deficient liver regeneration after carbon tetrachloride injury in mice lacking type 1 but not type 2 tumor necrosis factor receptor. Am J Pathol 152 (1998) 1577-1589
29. Kita H., Mackay I.R., Van De Water J., and Gershwin M.E. The lymphoid liver: considerations on pathways to autoimmune injury. Gastroenterology 120 (2001) 1485-1501
30. Heneghan M.A., and McFarlane I.G. Current and novel immunosuppressive therapy for autoimmune hepatitis. Hepatology 35 (2002) 7-13
31. Lohr H.F., Schlaak J.F., Lohse A.W., Bocher W.O., Arenz M., Gerken G., et al. Autoreactive CD4+ LKM-specific and anticlonotypic T-cell responses in LKM-1 antibody-positive autoimmune hepatitis. Hepatology 24 (1996) 1416-1421
32. Rothe J., Lesslauer W., Lotscher H., Lang Y., Koebel P., Kontgen F., et al. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 364 (1993) 798-802
33. Nowak M., Gaines G.C., Rosenberg J., Minter R., Bahjat F.R., Rectenwald J., et al. LPS-induced liver injury in d-galactosamine-sensitized mice requires secreted TNF-alpha and the TNF-p55 receptor. Am J Physiol Regul Integr Comp Physiol 278 (2000) R1202-R1209
34. Grell M., Douni E., Wajant H., Lohden M., Clauss M., Maxeiner B., et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 83 (1995) 793-802
35. Kusters S., Tiegs G., Alexopoulou L., Pasparakis M., Douni E., Kunstle G., et al. In vivo evidence for a functional role of both tumor necrosis factor (TNF) receptors and transmembrane TNF in experimental hepatitis. Eur J Immunol 27 (1997) 2870-2875
36. Alexopoulou L., Pasparakis M., and Kollias G. A murine transmembrane tumor necrosis factor (TNF) transgene induces arthritis by cooperative p55/p75 TNF receptor signaling. Eur J Immunol 27 (1997) 2588-2592
37. Yoshioka Y., Tsutsumi Y., Nakagawa S., and Mayumi T. Recent progress on tumor missile therapy and tumor vascular targeting therapy as a new approach. Curr Vasc Pharmacol 2 (2004) 259-270
38. Mukai Y., Yoshioka Y., and Tsutsumi Y. Phage display and PEGylation of therapeutic proteins. Comb Chem High Throughput Screen 8 (2005) 145-152